SCHEMBL2870452

SCHEMBL2870452

CN(C)S(=O)(=O)CC(C)(C)NC(=O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CA1 P00915 5/20 0.48
CA2 P00918 5/20 0.48
CA12 O43570 2/20 0.48
CA9 Q16790 2/20 0.48
CTSS P25774 4/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CTSL P07711 3/20 0.44
CTSB P07858 3/20 0.44
CTSK P43235 3/20 0.44
LMNA P02545 3/20 0.44
ACHE P22303 3/20 0.43
ALDH1A1 P00352 2/20 0.43
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2873030 0.85 CA1 (0.51) SMN1; SMN2MEN1KMT2ACA1CA2
SCHEMBL2873356 0.84 CA1 (0.50) SMN1; SMN2MEN1KMT2ACA1CA2
SCHEMBL2873755 0.84 CA2 (0.57) SMN1; SMN2MEN1KMT2ACA1CA2
SCHEMBL2870594 0.84 CA1 (0.50) SMN1; SMN2MEN1KMT2ACA1CA2
SCHEMBL2873353 0.83 MEN1 (0.49) SMN1; SMN2MEN1KMT2ACA1CA2
SCHEMBL2878022 0.83 MEN1 (0.49) SMN1; SMN2MEN1KMT2ACA1CA2
SCHEMBL2188090 0.81 SMN1; SMN2 (0.52) SMN1; SMN2MEN1KMT2ACA1CA2
SCHEMBL2870839 0.81 CA1 (0.49) SMN1; SMN2MEN1KMT2ACA1CA2
SCHEMBL2873085 0.81 MEN1 (0.47) SMN1; SMN2MEN1KMT2ACA1CA2
SCHEMBL8282485 0.79 MEN1 (0.58) SMN1; SMN2MEN1KMT2ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120965-B1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS INC (US) 2014-11-05 EP disclosed
US-8415497-B2 N-halogenated amino compounds and derivatives NOVABAY PHARMACEUTICALS, INC. (US) 2013-04-09 US disclosed
US-8415497-B2 N-halogenated amino compounds and derivatives NOVABAY PHARMACEUTICALS, INC. (US) 2013-04-09 US disclosed
US-8415497-B2 N-halogenated amino compounds and derivatives NOVABAY PHARMACEUTICALS, INC. (US) 2013-04-09 US disclosed
US-20100311791-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS, INC. 2010-12-09 US disclosed
US-20100311791-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS, INC. 2010-12-09 US disclosed
US-20100311791-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS, INC. 2010-12-09 US disclosed
EP-2120965-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES Novabay Pharmaceuticals, Inc. (US) 2009-11-25 EP disclosed
WO-2008083347-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES NOVABAY PHARMACEUTICALS, INC. (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311791-A1 N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES DCTD, DDC, DAO SMN1; SMN2 4442/4885MEN1 2339/4885KMT2A 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.